Manu Ohri
Board Member
Axil Brands, Inc. (AXIL)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Manu Ohri
Manu Ohri is recorded as Board Member at Axil Brands, Inc. (AXIL). Earlier roles on record: CFO at GT Biopharma, Inc. (GTBP) until June 3, 2024. GT Biopharma, Inc. reported in an 8-K filed June 7, 2024 that Manu Ohri was terminated as Chief Financial Officer, effective June 3, 2024. The proxy statement of GT Biopharma, Inc. reports total compensation of $1,129,671 for Manu Ohri in fiscal 2023, including a base salary of $432,000. Disclosed compensation is on record for 3 fiscal years.
“On June 3, 2024, Manu Ohri's employment as Chief Financial Officer at GT Biopharma, Inc. (the "Company") was terminated.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
-
Start not stated–2024-06-03
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Axil Brands, Inc.
Other people whose current roles at this company are on record from its filings.
- Jeff Toghraie CEO, Board Member
- Jeff Brown CFO, COO, Chief Accounting Officer, Board Member
- Meenu Jain CFO
- Monica Diaz Brickell CFO
- Jeffrey Brown Board Member
- Nancy Hundt Board Member
- Thomas Penna Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | GT Biopharma, Inc. (GTBP) | Chief Financial Officer and Secretary | $432,000 | $1,129,671 |
| 2022 | GT Biopharma, Inc. (GTBP) | Chief Financial Officer and Secretary | $334,512 | $944,544 |
| 2021 | GT Biopharma, Inc. (GTBP) | Chief Financial Officer and Secretary | — | — |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.